New MET inhibitor DO-2 enters human trials for Hard-to-Treat cancers

NCT ID NCT05752552

Recruiting now Disease control Sponsor: DeuterOncology Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing a new drug called DO-2 in people with advanced solid tumors (like lung cancer) that have a specific genetic change (MET mutation) and have run out of standard treatments. The main goal is to check the drug's safety and how the body processes it. About 55 participants will take DO-2 pills, and researchers will monitor side effects and any tumor shrinkage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DO-2 (a MET kinase inhibitor)
What this could lead to: If successful, this could lead to a new treatment option for patients with advanced solid tumors that have specific MET mutations.
What could go wrong: This is an early Phase 1 trial with only 55 participants, so it is primarily testing safety and dosing. It may not show strong anti-tumor effects, and side effects are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADULT SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer hereditary papillary renal cell carcinoma lung cancer lung neoplasm neoplasm non-small cell lung carcinoma refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADULT SOLID TUMOR ADVANCED SOLID TUMOR HEREDITARY RENAL PAPILLARY CANCER LUNG CANCER NON-SMALL CELL CARCINOMA NON-SMALL CELL LUNG CANCER REFRACTORY TUMOR

Contacts and locations

Locations

Centre Antoine Lacassagne
NOT_YET_RECRUITING

Nice, France
Centre Hospitalier Universitaire De Rennes
RECRUITING

Rennes, France
Centre Léon Bérard
RECRUITING

Lyon, France
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
RECRUITING

Rotterdam, Netherlands
Hôpitaux Universitaires de Marseille Timone
NOT_YET_RECRUITING

Marseille, 13385, France
Institut Bergonie
RECRUITING

Bordeaux, France
Institut Cœur Poumon - CHU Lille
RECRUITING

Lille, France
Institut Gustave Roussy
NOT_YET_RECRUITING

Villejuif, France
Institut Roi Albert II - UC Louvain
RECRUITING

Brussels, Belgium
Radboud UMC
RECRUITING

Nijmegen, Netherlands
UZ Leuven
RECRUITING

Leuven, Belgium
UZA
RECRUITING

Edegem, Belgium
Universitair Ziekenhuis Gent
RECRUITING

Ghent, 9000, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.